Avdoralimab
Avdoralimab Uses, Dosage, Side Effects, Food Interaction and all others data.
Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
| Trade Name | Avdoralimab |
| Generic | Avdoralimab |
| Avdoralimab Other Names | Avdoralimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How Avdoralimab works
Avdoralimab binds and inhibits C5a receptors (C5aR) expressed on myeloid-derived suppressor cells and neutrophils. C5a is often associated with tumors; by blocking the binding of C5a to C5aR, Advoralimab reduces the activation of MDSC and neutrophils in tumor microenvironments, thus exhibiting anti-tumor activity.
Innovators Monograph
You find simplified version here Avdoralimab
